# US 2017/0283402 A1 · Poly(ADP-Ribose) Polymerase 1 Inhibitors Structurally Unrelated to NAD

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283402 A1
- Document ID: US20170283402A1
- Status: Published application
- Kind: A1
- Application number: 15/515,773
- Filed: 2015-09-30
- Published: 2017-10-05
- Earliest claimed: 2014-10-03
- Assignees: Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center
- Applicants: Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center
- Inventors: Alexei Tulin
- Web page: https://patentgrep.com/patent/US20170283402A1

## CPC

- C07D 405/14: containing three or more hetero rings
- A61P 35/00: Antineoplastic agents
- C07D 207/06: with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D 263/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 295/15: to an acyclic saturated chain
- C07D 317/28: Radicals substituted by nitrogen atoms (nitro radicals C07D317/16)
- C07D 317/72: spiro-condensed with carbocyclic rings
- C07D 319/06: not condensed with other rings
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 407/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds that are not related to NAD, and which target PARP1-histone H4 interaction are provided, as well as compositions of these compounds, and methods for specific inhibition of poly(ADP-ribose) polymerase 1 (PARP-1) using these compounds are provided. These PARP-1 inhibitors may be used to treat cancer in which PARP-1 activation or biologic activity plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.

## Claims

### Claim 1

A compound of Formula
wherein:
R1 is an alkyl or ether group;
R2 is either CH3 or not present, wherein when R2 is CH3, the nitrogen atom is positively charged, and
R3 is either
wherein R4 includes one or more ring structures;
provided that the compound is not

### Claim 2 (depends on 1)

The compound of claim 1, wherein R3 comprises:

### Claim 3 (depends on 2)

The compound of claim 2, wherein the R1 comprises —(CH2)3—.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The compound of claim 1, wherein the compound comprises:

### Claim at position 6

6-7. (canceled)

### Claim 8 (depends on 2)

The compound of claim 2, wherein the R1 comprises —(CH2)O(CH2)—.

### Claim 9 (depends on 8)

The compound of claim 8, wherein the compound comprises:

### Claim 10 (depends on 2)

The compound of claim 2, wherein the R1 comprises —(CH2)2—.

### Claim 11 (depends on 10)

The compound of claim 10, wherein the compound comprises:

### Claim 12 (depends on 1)

The compound of claim 1, wherein R3 comprises:

### Claim 13 (depends on 12)

The compound of claim 12, wherein R1 comprises —(CH2)3—.

### Claim 14 (depends on 13)

The compound of claim 13, wherein the compound comprises:

### Claim at position 14

15-18. (canceled)

### Claim 19 (depends on 12)

The compound of claim 12, wherein R1 comprises —(CH2)O(CH2)—.

### Claim 20 (depends on 19)

The compound of claim 19, wherein the compound comprises:

### Claim 21

(canceled)

### Claim 22 (depends on 12)

The compound of claim 12, wherein R1 comprises —(CH2)2—.

### Claim 23 (depends on 22)

The compound of claim 22, wherein the compound comprises:

### Claim 24

(canceled)

### Claim 25

A compound comprising

### Claim 26

(canceled)

### Claim 27 (depends on 1)

A composition, comprising the compound of claim 1 and a carrier.

### Claim 28 (depends on 27)

The composition of claim 27, wherein the carrier is a pharmaceutically acceptable carrier.

### Claim 29

A method for inhibiting the biologic activity of poly(ADP-ribose) polymerase 1 (PARP1), comprising contacting PARP1 with an amount of a compound effective to inhibit the biologic activity of PARP1, the compound comprising:
wherein:
R1 is an alkyl or ether group;
R2 is either CH3 or not present, wherein when R2 is CH3, the nitrogen atom is positively charged, and
R3 is either
wherein R4 includes one or more ring structures.

### Claim at position 26

30-54. (canceled)

### Claim 55

A method for inhibiting the biologic activity of poly(ADP-ribose) polymerase 1 (PARP1), comprising contacting PARP1 with an amount of a compound effective to inhibit the biologic activity of PARP1, the compound comprising:

### Claim at position 28

56-67. (canceled)

### Claim 68

A method for treating a cancer patient, comprising administering to the patient in need thereof an effective amount of the compound of Formula
wherein:
R1 is an alkyl or ether group;
R2 is either CH3 or not present, wherein when R2 is CH3, the nitrogen atom is positively charged, and
R3 is either
wherein R4 includes one or more ring structures, thereby treating the cancer in the patient.

### Claim 69

(canceled)

### Claim 70 (depends on 68)

The method of claim 68 wherein:
the cancer patient is a prostate cancer patient and the cancer is prostate cancer;
the cancer patient is a breast cancer patient and the cancer is breast cancer;
the cancer patient is a kidney cancer patient and the cancer is kidney cancer;
the cancer patient is an ovarian cancer patient and the cancer is ovarian cancer;
the cancer patient is a glioblastoma patient and the cancer is glioblastoma;
the cancer patient is a lymphoma patient and the cancer is lymphoma; or
the cancer patient is a leukemia patient and the cancer is leukemia.

### Claim at position 32

71-94. (canceled)
